Based on the data retrieved in this study, we found that the ATR inhibitor AZD6738 can enhance the cytotoxic effects induced by gemcitabine, a ribonucleotide reductase inhibitor, in bladder cancer cells. This evidence concerns the gene ATR and urinary bladder carcinoma.